Secondary analysis of the D2EFT trial: in 727 sequences from participants failing first-line HIV-1 therapy in 14 countries, high-level resistance to lamivudine and emtricitabine was 88.3%; M184V/I was found in 86.2% and K103N in 57.8%, more often in Africa and South America.
Secondary analysisn = 727 sequences
Obeng et al. Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial